Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more
Autolus Therapeutics plc (6A3A) - Total Assets
Latest total assets as of September 2025: €661.95 Million EUR
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) holds total assets worth €661.95 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Autolus Therapeutics plc - Total Assets Trend (2017–2024)
This chart illustrates how Autolus Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Autolus Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Autolus Therapeutics plc's total assets of €661.95 Million consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.1% |
| Accounts Receivable | €15.00K | 0.0% |
| Inventory | €4.14 Million | 0.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €12.37 Million | 1.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Autolus Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Autolus Therapeutics plc's current assets represent 84.4% of total assets in 2024, a decrease from 95.8% in 2017.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2024, down from 92.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 1.6% of total assets.
Autolus Therapeutics plc Competitors by Total Assets
Key competitors of Autolus Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Autolus Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Autolus Therapeutics plc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Autolus Therapeutics plc is currently not profitable relative to its asset base.
Autolus Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 13.69 | 5.86 |
| Quick Ratio | 5.86 | 13.69 | 5.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €431.51 Million | € 665.64 Million | € 163.35 Million |
Autolus Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Autolus Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 108.5% |
| Total Assets | €782.73 Million |
| Market Capitalization | $140.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Autolus Therapeutics plc's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Autolus Therapeutics plc's assets grew by 108.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Autolus Therapeutics plc (2017–2024)
The table below shows the annual total assets of Autolus Therapeutics plc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €782.73 Million | +108.51% |
| 2023-12-31 | €375.38 Million | -23.43% |
| 2022-12-31 | €490.27 Million | +20.89% |
| 2021-12-31 | €405.56 Million | +37.83% |
| 2020-12-31 | €294.24 Million | -3.06% |
| 2019-12-31 | €303.53 Million | +11.10% |
| 2018-12-31 | €273.20 Million | +83.78% |
| 2017-12-31 | €148.66 Million | -- |